Clinical trials: Butyrate
Leukemia, Lymphoma
Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus
RATIONALE: The Epstein Barr virus can cause cancer and lymphoproliferative disorders. Ganciclovir is an antiviral drug that acts against the Epstein Barr virus.
- Conditions
- Leukemia, Lymphoma, Precancerous Condition, Small Intestine Cancer
- Trial name
- NCT00006340
- Testing
- arginine butyrate, ganciclovir
- Where
- 6 sites in United States, France and 2 more
- Sponsor
- Boston Medical Center
Hirschsprung's Disease
Effects of Butyrate Enemas on Postoperative Intestinal Motility Disorders in Hirschsprung's Disease
Hirschsprung's disease (HD) is a rare congenital disorder (1/5000) defined by the absence of ganglion cells in the submucosal and myenteric plexuses along a variable length of the digestive tract.
- Trial name
- Buty-Hirsch (NCT03660176)
- Testing
- Sodium Butyrate, routine management
- Where
- France
- Volunteers
- 58 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Safety Issues
Tolerability and Modulatory Action of the Butyrate Releaser N-(1-carbamoyl-2-phenyl-ethyl) Butyramide
Accumulating evidence is showing that gut microbiota could play a key role in gastrointestinal tract and immune system development and function. Many beneficial effects elicited by gut microbiota are mediated its metabolites.
- Trial name
- NCT04491266
- Testing
- FBA
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Federico II University
Irritable Bowel Syndrome (IBS), Children, Only
Butyrate in Children With IBS: Double Blind Placebo Controlled Randomized Clinical Trial
We will perform a randomized, double-blind, placebo-controlled trial to establish whether calcium butyrate relieves symptoms in children with irritable bowel syndrome (IBS).
- Trial name
- BUZIR (NCT04566679)
- Testing
- Dibuzin
- Where
- 2 sites in Italy
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Bari
Ulcerative Colitis
The Use of Butyrate Therapy in Pediatric Ulcerative Colitis
Butyrate is an important metabolite produced by the gut microbiome and has been shown as a helpful therapy in ulcerative colitis.
- Trial name
- NCT05218850
- Testing
- Butyrate
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Children's Hospital Los Angeles
Very Low Birth Weight Preterms
Effects of Recto-colic Enemas of Butyrate on the Digestive Disorders of Very Low Birth Weight Preterms <1250 Grams
Clinical management of very low birth weight newborns (VLBW <1250g) consists in several challenges to adapt immature physiological systems to extrauterine life.
- Trial name
- NEOTRANS (NCT01536483)
- Testing
- Butyrate enemas
- Where
- France
- Volunteers
- 61 people
- Sponsor
- Nantes University Hospital
Rett Syndrome, Dysbiosis
Protective Role of Pre-/ Post-biotics on Gut Inflammation, Dysbiosis, and Life Quality in Rett Syndrome (Biotics_RTT)
The study will examine the potential efficacy and safety of two pre- and post-biotics on markers for gut inflammation and intestinal microbiota ecology in patients with Rett syndrome.
- Conditions
- Rett Syndrome, Dysbiosis, Epilepsy, Quality of Life
- Trial name
- Biotics_RTT (NCT05420805)
- Testing
- ALAC, inulin, FOS, and sodium butyrate, Sodium butyrate and zinc oxide
- Where
- Italy
- Volunteers
- 28 people
- Sponsor
- Azienda Ospedaliera Universitaria Senese
Insulin Resistance, Obesity
The Effects of Butyrate on Children With Obesity
Butyrate is a short chain fatty acid (SCFA) produced by bacterial fermentation of undigested starch in the gut. Butyrate carries out different effects at intestinal and extraintestinal level, including: immune regulation with…
- Trial name
- NCT02721953
- Testing
- Butyrate
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Federico II University
Inflammatory Bowel Diseases
Butyrate in Pediatric Inflammatory Bowel Disease
The first prospective randomised placebo-controlled study in the IBD pediatric population was conducted to evaluate the effectiveness of oral sodium butyrate as add-on therapy in IBD.
- Trial name
- NCT05456763
- Testing
- sodium butyrate
- Volunteers
- 100 people
- Sponsor
- Centre of Postgraduate Medical Education
Chronic Mesenteric Ischemia
Chronic Mesenteric Ischemia Breath Testing
Background and aims: A gold standard diagnostic test to diagnose chronic mesenteric ischemia is currently lacking. Isotope labelled-butyrate and glucose breath testing could theoretically quantify mucosal oxygen consumption and…
- Trial name
- NCT06022588
- Testing
- Sodium butyrate, 1-13C, 99%, Cambridge Isotope Laboratories, Inc.USA, U-13C6, 99%; Cambridge Isotope Laboratories, Inc.USA, Breath test
- Where
- Netherlands
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Erasmus Medical Center
Autism Spectrum Disorder (ASD)
Butyrate Supplementation in Children With Autism Spectrum Disorder (ASD) and Functional Gastrointestinal Disorders
Autism spectrum disorder (ASD) is a neurodevelopmental condition occurring in 1:77 Italian children. Several comorbidities are reported, including functional gastrointestinal disorders (FGIDs) present in up to 70% of patients.
- Trial name
- b(AUT)yrate (NCT06514573)
- Testing
- Sodium Butyrate
- Where
- 3 sites in Italy
- Volunteers
- 128 people
- Sponsor
- Istituto Superiore di Sanità
Eczema
Randomised, Double-blind, Placebo-controlled Study of Topical Clobetasone Butyrate 0.05% Cream in Subjects With Eczema for Two Weeks to Evaluate the Efficacy and Safety
This was a multicenter, randomised, double-blind, two treatment arms, vehicle (cream base) -controlled, parallel-group study in subjects with moderate to severe eczema (defined by investigators global assessment (IGA) score…
- Trial name
- NCT01567995
- Testing
- Clobetasone Butyrate 0.05% Cream, Vehicle (base cream)
- Where
- 7 sites in China
- Volunteers
- 240 people
- Sponsor
- GlaxoSmithKline
Atopic Dermatitis
Therapeutic Efficacy of Cutaneous Application of Postbiotic N-(1-carbamoyl-2-phenyl-ethyl) Butyramide (FBA) in Pediatric Subjects Affected by Atopic Dermatitis
Atopic dermatitis (AD) is a chronic, multifactorial inflammatory skin disease characterized by eczematous skin and pruritus and it's due to an alteration of the skin barrier and of the intestinal and skin microbiome (SM), which…
- Trial name
- BuPAD (NCT07016087)
- Testing
- Cosmetic formulation experimental, Cosmetic formulation usual
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Federico II University
Beta-Thalassemia
Phase II Study of Arginine Butyrate With or Without Epoetin Alfa in Patients With Thalassemia Intermedia
OBJECTIVES: I. Determine whether arginine butyrate with or without epoetin alfa can stimulate gamma-globin chain production to a degree that decreases anemia and results in hematologic improvement in patients with thalassemia…
- Trial name
- NCT00006136
- Testing
- arginine butyrate, epoetin alfa
- Where
- 7 sites in United States, United Kingdom
- Volunteers
- 15 people
- Sponsor
- Boston University
Skin Ulcers, Sickle Cell Anemia
Phase II Randomized Trial:Arginine Butyrate Plus Standard Local Therapy in Patients With Refractory Sickle Cell Ulcers
OBJECTIVES: I. Compare the efficacy of local care alone vs local care plus arginine butyrate in terms of healing rate in patients with refractory sickle cell ulcers. II.
- Trial name
- NCT00004412
- Testing
- Arginine Butyrate, Standard local care dressing
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Susan P. Perrine
Obesity, Childhood
Effects of Butyrate Against Pediatric Obesity
Worldwide obesity is a public health concern that is defined by the World Health Organization as abnormal or excessive fat accumulation that may impair health.
- Trial name
- BAPO (NCT04620057)
- Testing
- butyrate
- Where
- Italy
- Volunteers
- 54 people
- Sponsor
- Federico II University
EBV Lymphomas, Lympho-proliferative Diseases
Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies
The purpose of this study is to assess whether administration of Arginine Butyrate + ganciclovir/valganciclovir for up to three 21-day cycles is tolerable, and results in partial or complete responses in patients with EBV(+)…
- Trial name
- NCT00917826
- Testing
- Arginine Butyrate, Ganciclovir, Valganciclovir
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- HemaQuest Pharmaceuticals Inc.